Literature DB >> 35272393

Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.

Kazuyoshi Ogasawara1, Shusuke Numata2, Naomi Hasegawa3, Masahito Nakataki4, Manabu Makinodan5, Kazutaka Ohi6, Masahiro Takeshima7, Takashi Tsuboi8, Naoki Hashimoto9, Toshiaki Onitsuka10, Hiroyuki Muraoka11, Hikaru Hori12, Kayo Ichihashi13, Takahiko Inagaki14,15, Norio Yasui-Furukori16, Akitoyo Hishimoto17, Nobuhiro Sugiyama18, Kentaro Fukumoto19, Tatsuya Nagasawa20, Junya Matsumoto3, Yoshikazu Takaesu21, Ryuji Furihata22, Kiyotaka Nemoto23, Toshinori Nakamura18, Masahide Usami24, Kenichiro Miura3, Michiko Fujimoto25, Hiromi Tagata26, Hisashi Yamada27, Hiroshi Komatsu28, Shinichiro Ochi29, Kiyokazu Atake30, Eiichi Katsumoto31, Mikio Kido32,33, Taishiro Kishimoto34, Taro Suwa35, Satoshi Yamamura36, Jun-Ichi Iga29, Hitoshi Iida12, Ken Inada11, Koichiro Watanabe8, Ryota Hashimoto3.   

Abstract

The Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) project, which is a nationwide dissemination and implementation program for clinical practice guidelines (CPGs) in the field of psychiatry, is currently ongoing. In the current study, a subjective assessment of the participants in the EGUIDE programs was assessed using a questionnaire. Then, the relationships between the subjective assessment, the characteristics of the participants, and the clinical knowledge of the CPGs were evaluated. More than 90% of the participants gave a high rating for the components of content, recommendation, knowledge, skill, and adherence, but not for the component of confidence. A positive correlation was found between years of professional experience and the score of confidence. These results suggest that it may be necessary to apply the knowledge and skills of CPGs obtained in the education programs into practice to increase confidence in the proper use of psychiatric therapies based on CPGs.
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Entities:  

Keywords:  clinical practice guidelines; depression; dissemination; education; implementation; schizophrenia; subjective assessment

Mesh:

Year:  2022        PMID: 35272393      PMCID: PMC9216374          DOI: 10.1002/npr2.12245

Source DB:  PubMed          Journal:  Neuropsychopharmacol Rep        ISSN: 2574-173X


INTRODUCTION

Clinical practice guidelines (CPGs) that give medical practitioners and patients reasonable treatment recommendations are important in “evidence‐based medicine,” which is the standard manner of today's medical practices. The Effectiveness of Guideline for Dissemination and Education in psychiatric treatment (EGUIDE) project, which is a nationwide dissemination and implementation project for CPGs in the field of psychiatry, is currently ongoing. This project addresses "Treatment Guidelines II. Major Depressive Disorder" by the Japanese Society of Mood Disorders and "Guidelines for the Pharmacological Treatment of Schizophrenia" by the Japanese Society of Neuropsychopharmacology. The project is original in that it evaluates multiple indicators and provides feedback on the lecture and development of CPGs. As of June 2021, 243 medical institutions, including 44 universities, were participating in this project in Japan. The aim was that by promoting the EGUIDE project, psychiatrists will be educated to use the CPGs and that more appropriate treatments, based on CPGs, will be widely provided. To date, it has been demonstrated that guideline‐based treatment is not always widely used in Japan, , that participation in the EGUIDE programs improves understanding of the CPGs, that revisions of the training materials of EGUIDE programs improve participants' understanding of the CPGs, and that polypharmacy of antipsychotics significantly increases the simultaneous prescription of other psychotropics such as anticholinergics, anxiolytics, hypnotics, and mood‐stabilizing agents in patients with schizophrenia. In the current study, the subjective assessment of the participants in the EGUIDE programs was assessed using a questionnaire. Then, the relationships between the subjective assessment, the characteristics of the participants, and the clinical knowledge of the CPGs were assessed.

METHOD

Participants

Psychiatrists were recruited from October 2016 to March 2018. Four sets of data, the subjective assessments of schizophrenia (SCZ) and major depressive disorder (MDD) programs and the clinical knowledge of the CPGs of SCZ and MDD, were available for a total of 344 participants. The mean age of the participants was 33.8 ± 6.9 years (mean ± SD), and the mean years of professional experience were 5.1 ± 6.1 years.

Subjective assessment of EGUIDE programs

The subjective assessment of each guideline program was evaluated using a questionnaire following the EGUIDE programs. It is a self‐administered questionnaire that consists of the following six components on a scale of 1‐5, with higher scores indicating a higher evaluation: (1) How would you rate the content of this course? The abbreviation for this question is "Content," with 5 = very satisfactory; 4 = moderate satisfaction; 3 = I cannot say I was either satisfied or dissatisfied; 2 = dissatisfied; and 1 = very dissatisfied; (2) How would you rate your recommendation of this course to a colleague or junior colleague? The abbreviation for this question is "Recommendation," with 5: strong recommendation; 4 = moderate recommendation; 3 = I cannot say that I would or would not recommend; 2 = no recommendation; and 1 = no recommendation at all; (3) How would you rate your clinical knowledge of treatment after attending this course? The abbreviation for this question is "Knowledge," with 5 = very increased; 4 = increased; 3 = I cannot say increased or confused; 2 = confused; 1 = very confused; (4) How would you rate your treatment skills after attending this course? The abbreviation for this question is "Skill," with 5 = very increased; 4 = increased; 3 = I cannot say increased or confused; 2 = confused; 1 = very confused; (5) How would you rate your confidence in your ability to perform proper treatment after attending this course? The abbreviation for this question is "Confidence," with 5 = great confidence; 4 = moderate confidence; 3 = I cannot say I am confident or unsure; 2 = no confidence; 1 = no confidence at all; and (6) How would you rate your future choice of treatment according to the guidelines after attending this course? The abbreviation for this is "Adherence," with 5 = will always choose; 4 = will mostly choose; 3 = I cannot say I would choose or not; 4 = no consideration of guidelines; 1 = no consideration of guidelines at all.

Assessment of clinical knowledge of CPGs

Working knowledge of the CPGs of SCZ and MDD was evaluated using a questionnaire both at baseline and after each of the programs. Each self‐administered questionnaire consists of 37 questions, with a total score of 37 points (see Tables S1 and S2).

Statistical analysis

The relationships between the demographic characteristics of the participants (age and professional experience), the total score of clinical knowledge following the programs, and each component score of subjective assessment (the aforementioned content, recommendation, knowledge, skill, confidence, and adherence) were analyzed using Spearman's rank correlation coefficient. All statistical analyses were performed using IBM SPSS 27.

RESULTS

In the subjective assessment, more than 90% of the participants gave a high rating of 4 or 5 for the five components of content (98.8% and 97.7%), recommendation (95.3% and 97.1%), knowledge (98.3% and 98.5%), skill (92.4% and 91.0%), and adherence (95.3% and 96.5%), respectively, in both the SCZ and MDD programs, but not for the component of confidence (42.2% and 44.8%, respectively, Figure 1). When we examined the relationships between age, professional experience, and the individual component scores of the subjective assessment, a positive correlation was found between years of professional experience and the score of confidence both in the SCZ and MDD programs (r = .249, P = 2.97 × 10−6 and r = .151, P =.005, respectively; Table 1). This correlation reached statistical significance when corrected for the multiple testing of the six components in each program (P < .0083). When the relationships between each component score of the subjective assessment and the total score of clinical knowledge of the CPGs were assessed following the programs, no significant association was found in either the SCZ or MDD programs (P > .05; Table S3).
FIGURE 1

Scores of the distribution of subjective assessment. Each cumulative bar chart represents the proportion of the subjective assessment score of the schizophrenia (SC) and major depressive disorder (MDD) guideline programs. The six components were rated on a scale of 1‐5 using a self‐administered questionnaire following the EGUIDE programs, with a higher score indicating a higher evaluation

TABLE 1

Correlations between subjective assessments and age/years of professional experience. Spearman's rank correlation coefficient: The statistical significanec level was set at P <.0083 for the correction of the multiple testing of six components in each program

ContentRecommendationsKnowledgeSkillsConfidenceCompliance
Schizophrenia
Age (y)
r .040.107−.102−.115.126.058
P value.455.048.060.033.019.287
Professional experience (y)
r −.008.088−.142−.165.249.069
P value.882.104.009.002 2.97 × 10−6 .202
Major depressive disorder
Age (y)
r .019.118−.073−.066.093−.007
P value.725.029.175.224.085.898
Professional experience (y)
r −.030.072−.181−.127.151.058
P value.574.181.001.019 .005 .287

Bold value indicates significant positive correlations are observed between "Confidence" and years of professional experience in either the schizophrenia or major depressive disorder program.

Scores of the distribution of subjective assessment. Each cumulative bar chart represents the proportion of the subjective assessment score of the schizophrenia (SC) and major depressive disorder (MDD) guideline programs. The six components were rated on a scale of 1‐5 using a self‐administered questionnaire following the EGUIDE programs, with a higher score indicating a higher evaluation Correlations between subjective assessments and age/years of professional experience. Spearman's rank correlation coefficient: The statistical significanec level was set at P <.0083 for the correction of the multiple testing of six components in each program Bold value indicates significant positive correlations are observed between "Confidence" and years of professional experience in either the schizophrenia or major depressive disorder program.

DISCUSSION

To our knowledge, this is the first study that assessed the subjective effect of educational program and the related factors in the field of psychiatric CPGs. The subjective assessment of participants in the EGUIDE programs was performed using a questionnaire. High rating scores of content and recommendation suggest that the CPG programs were highly regarded by the participants. High ratings of knowledge and skill suggest that most participants had a better understanding of CPGs. These results are consistent with the previous results of the objective improvement of the participants' clinical knowledge of the CPGs. Although knowledge of the guidelines may not be necessarily linked to treatment outcomes, a high rating score of adherence may lead to future proper treatment choices based on the CPGs. A high rating for confidence was not achieved in either the SCZ or MDD programs. Most participants might be cautious rather than focusing on building their confidence. While the score of confidence was associated with years of professional experience, it was not associated with clinical knowledge of CPGs following the programs. On the contrary, an education program using case‐based learning and supervision over time increased confidence as well as knowledge. Evidence‐based medicine, which the CPGs are intended to support, relies on the expertise of medical practitioners. , In other words, clinical experience is a prerequisite for the optimal use of the probabilistic recommendations provided by the CPGs in practice. It may be that an application of the clinical knowledge of CPGs acquired in the program in daily practice will lead to the acquisition of confidence in the appropriate use of psychiatric therapies. A longitudinal study of changes in adherence to CPGs and confidence of the proper therapies based on CPGs is currently planned. The limitations of this study are the number of participants and potential sampling bias, such as years of professional experience. Future researches with increased participants are needed.

CONCLUSION

The educational programs on CPGs contributed to a high subjective assessment of therapy knowledge and skills, as well as guideline‐based treatment choices, but did not lead to an increased confidence in the appropriate use of therapies based on CPGs. To increase confidence, it may be necessary to apply the knowledge and skills obtained in the educational programs to real‐world clinical practice.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

KOg and SN were involved in data collection and data analysis and wrote the first draft of the manuscript. NHase, JM, KM, and MN were involved in the data analysis and contributed to the interpretation of the data and writing of the manuscript. MM, KOh, MT, TT, NHash, TO, HM, HH, KIc, TI, NY‐F, AH, NS, KF, TNag, YT, RF, KN, TNak, MU, MF, HT, HY, HK, SO, KA, EK, MK, TK, TS, SY, JI, and HI contributed to the interpretation of the data and data collection. KIn and KW were involved in the study design and contributed to the interpretation of the data. RH supervised the entire project, collected the data, and was involved in the design, analysis, and interpretation of the data. All authors contributed to and approved the final article.

APPROVAL OF THE RESEARCH PROTOCOL BY AN INSTITUTION REVIEWER BOARD

This study was approved by the ethics committees of the National Center of Neurology and Psychiatry (A2017‐105) and each participating university, hospital and clinic.

INFORMED CONSENT

All participants provided their written informed consent. Public availability of raw data was not planned in the research protocol approved by an Institution Reviewer Board. We did not obtain informed consent of the public availability.

REGISTRY AND THE REGISTRATION NO. OF THE STUDY/TRIAL

The protocol of this study was registered in the University Hospital Medical Information Network registry (UMIN000022645).

ANIMAL STUDIES STATEMENT

Not applicable. Tables S1‐S3 Click here for additional data file.
  10 in total

1.  Physicians' and patients' choices in evidence based practice.

Authors:  R Brian Haynes; P J Devereaux; Gordon H Guyatt
Journal:  BMJ       Date:  2002-06-08

2.  Enhancing clinical practice in the management of distress: The Therapeutic Practices for Distress Management (TPDM) project.

Authors:  Deborah McLeod; Mary Jane Esplen; Jiahui Wong; Thomas F Hack; Lise Fillion; Doris Howell; Margaret Fitch; Julie Dufresne
Journal:  Psychooncology       Date:  2018-07-31       Impact factor: 3.894

3.  Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.

Authors:  Naoki Hashimoto; Norio Yasui-Furukori; Naomi Hasegawa; Shuhei Ishikawa; Shusuke Numata; Hikaru Hori; Hitoshi Iida; Kayo Ichihashi; Ryuji Furihata; Atsunobu Murata; Takashi Tsuboi; Masahiro Takeshima; Yoshitaka Kyou; Hiroshi Komatsu; Chika Kubota; Shinichiro Ochi; Yoshikazu Takaesu; Masahide Usami; Tatsuya Nagasawa; Akitoyo Hishimoto; Kenichiro Miura; Junya Matsumoto; Kazutaka Ohi; Hisashi Yamada; Ken Inada; Koichiro Watanabe; Kazutaka Shimoda; Ryota Hashimoto
Journal:  Asian J Psychiatr       Date:  2021-07-15

4.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

5.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

6.  Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.

Authors:  Yoshikazu Takaesu; Koichiro Watanabe; Shusuke Numata; Masaaki Iwata; Noriko Kudo; Satoru Oishi; Takeya Takizawa; Kiyotaka Nemoto; Yuka Yasuda; Hiromi Tagata; Takashi Tsuboi; Naohisa Tsujino; Naoki Hashimoto; Yuki Matsui; Hikaru Hori; Hidenaga Yamamori; Nobuhiro Sugiyama; Taro Suwa; Taishiro Kishimoto; Akitoyo Hishimoto; Masahide Usami; Ryuji Furihata; Kunihiro Iwamoto; Hiroshige Fujishiro; Toshinori Nakamura; Kentaro Mizuno; Takahiko Inagaki; Eiichi Katsumoto; Hiroaki Tomita; Kazutaka Ohi; Hiroyuki Muraoka; Kiyokazu Atake; Hitoshi Iida; Tatsuya Nagasawa; Junichi Fujita; Satoshi Yamamura; Toshiaki Onitsuka; Atsunobu Murata; Yoichiro Takayanagi; Hokuto Noda; Yukiko Matsumura; Kenji Takezawa; Jun-Ichi Iga; Kayo Ichihashi; Kazuyoshi Ogasawara; Hisashi Yamada; Ken Inada; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2019-08-22       Impact factor: 5.188

7.  Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.

Authors:  Kayo Ichihashi; Hikaru Hori; Naomi Hasegawa; Yuka Yasuda; Tomoya Yamamoto; Takashi Tsuboi; Kunihiro Iwamoto; Taishiro Kishimoto; Tadasu Horai; Hiroki Yamada; Nobuhiro Sugiyama; Toshinori Nakamura; Naohisa Tsujino; Kiyotaka Nemoto; Satoru Oishi; Masahide Usami; Eiichi Katsumoto; Hidenaga Yamamori; Hiroaki Tomita; Taro Suwa; Ryuji Furihata; Takahiko Inagaki; Junichi Fujita; Toshiaki Onitsuka; Kenichiro Miura; Junya Matsumoto; Kazutaka Ohi; Yuki Matsui; Yoshikazu Takaesu; Naoki Hashimoto; Junichi Iga; Kazuyoshi Ogasawara; Hisashi Yamada; Koichiro Watanabe; Ken Inada; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-06-30

8.  Unmet needs of patients with major depressive disorder - Findings from the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.

Authors:  Hitoshi Iida; Junichi Iga; Naomi Hasegawa; Yuka Yasuda; Tomoya Yamamoto; Kenichiro Miura; Junya Matsumoto; Atsunobu Murata; Kazuyoshi Ogasawara; Hisashi Yamada; Hikaru Hori; Kayo Ichihashi; Naoki Hashimoto; Kazutaka Ohi; Norio Yasui-Furukori; Takashi Tsuboi; Toshinori Nakamura; Masahide Usami; Ryuji Furihata; Yoshikazu Takaesu; Kunihiro Iwamoto; Nobuhiro Sugiyama; Taishiro Kishimoto; Naohisa Tsujino; Hiroki Yamada; Akitoyo Hishimoto; Kiyotaka Nemoto; Kiyokazu Atake; Hiroyuki Muraoka; Eiichi Katsumoto; Satoru Oishi; Takahiko Inagaki; Fumiaki Ito; Yayoi Imamura; Mikio Kido; Tatsuya Nagasawa; Shusuke Numata; Shinichiro Ochi; Masaaki Iwata; Hidenaga Yamamori; Junichi Fujita; Toshiaki Onitsuka; Satoshi Yamamura; Manabu Makinodan; Michiko Fujimoto; Yoichiro Takayanagi; Kenji Takezawa; Hiroshi Komatsu; Kentaro Fukumoto; Shinichiro Tamai; Hirotaka Yamagata; Chika Kubota; Tadasu Horai; Ken Inada; Koichiro Watanabe; Hiroaki Kawasaki; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2020-10-09       Impact factor: 5.188

9.  Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.

Authors:  Kazuyoshi Ogasawara; Shusuke Numata; Naomi Hasegawa; Masahito Nakataki; Manabu Makinodan; Kazutaka Ohi; Masahiro Takeshima; Takashi Tsuboi; Naoki Hashimoto; Toshiaki Onitsuka; Hiroyuki Muraoka; Hikaru Hori; Kayo Ichihashi; Takahiko Inagaki; Norio Yasui-Furukori; Akitoyo Hishimoto; Nobuhiro Sugiyama; Kentaro Fukumoto; Tatsuya Nagasawa; Junya Matsumoto; Yoshikazu Takaesu; Ryuji Furihata; Kiyotaka Nemoto; Toshinori Nakamura; Masahide Usami; Kenichiro Miura; Michiko Fujimoto; Hiromi Tagata; Hisashi Yamada; Hiroshi Komatsu; Shinichiro Ochi; Kiyokazu Atake; Eiichi Katsumoto; Mikio Kido; Taishiro Kishimoto; Taro Suwa; Satoshi Yamamura; Jun-Ichi Iga; Hitoshi Iida; Ken Inada; Koichiro Watanabe; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2022-03-10

10.  Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.

Authors:  Shusuke Numata; Masahito Nakataki; Naomi Hasegawa; Yoshikazu Takaesu; Masahiro Takeshima; Toshiaki Onitsuka; Toshinori Nakamura; Reon Edagawa; Hiroaki Edo; Kenichiro Miura; Junya Matsumoto; Norio Yasui-Furukori; Taishiro Kishimoto; Hikaru Hori; Takashi Tsuboi; Yuka Yasuda; Ryuji Furihata; Hiroyuki Muraoka; Shinichiro Ochi; Tatsuya Nagasawa; Yoshitaka Kyou; Atsunobu Murata; Eiichi Katsumoto; Kazutaka Ohi; Akitoyo Hishimoto; Ken Inada; Koichiro Watanabe; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2021-03-11
  10 in total
  3 in total

1.  Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.

Authors:  Hikaru Hori; Norio Yasui-Furukori; Naomi Hasegawa; Jun-Ichi Iga; Shinichiro Ochi; Kayo Ichihashi; Ryuji Furihata; Yoshitaka Kyo; Yoshikazu Takaesu; Takashi Tsuboi; Fumitoshi Kodaka; Toshiaki Onitsuka; Tsuyoshi Okada; Atsunobu Murata; Hiroko Kashiwagi; Hitoshi Iida; Naoki Hashimoto; Kazutaka Ohi; Hisashi Yamada; Kazuyoshi Ogasawara; Yuka Yasuda; Hiroyuki Muraoka; Masahide Usami; Shusuke Numata; Masahiro Takeshima; Hirotaka Yamagata; Tatsuya Nagasawa; Hiromi Tagata; Manabu Makinodan; Mikio Kido; Eiichi Katsumoto; Hiroshi Komatsu; Junya Matsumoto; Chika Kubota; Kenichiro Miura; Akitoyo Hishimoto; Koichiro Watanabe; Ken Inada; Hiroaki Kawasaki; Ryota Hashimoto
Journal:  Front Psychiatry       Date:  2022-05-17       Impact factor: 5.435

2.  Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.

Authors:  Norio Yasui-Furukori; Hiroyuki Muraoka; Naomi Hasegawa; Shinichiro Ochi; Shusuke Numata; Hikaru Hori; Akitoyo Hishimoto; Toshiaki Onitsuka; Kazutaka Ohi; Naoki Hashimoto; Tatsuya Nagasawa; Yoshikazu Takaesu; Takahiko Inagaki; Hiromi Tagata; Takashi Tsuboi; Chika Kubota; Ryuji Furihata; Jun-Ichi Iga; Hitoshi Iida; Kenichiro Miura; Junya Matsumoto; Hisashi Yamada; Koichiro Watanabe; Ken Inada; Kazutaka Shimoda; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2021-12-02

3.  Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.

Authors:  Kazuyoshi Ogasawara; Shusuke Numata; Naomi Hasegawa; Masahito Nakataki; Manabu Makinodan; Kazutaka Ohi; Masahiro Takeshima; Takashi Tsuboi; Naoki Hashimoto; Toshiaki Onitsuka; Hiroyuki Muraoka; Hikaru Hori; Kayo Ichihashi; Takahiko Inagaki; Norio Yasui-Furukori; Akitoyo Hishimoto; Nobuhiro Sugiyama; Kentaro Fukumoto; Tatsuya Nagasawa; Junya Matsumoto; Yoshikazu Takaesu; Ryuji Furihata; Kiyotaka Nemoto; Toshinori Nakamura; Masahide Usami; Kenichiro Miura; Michiko Fujimoto; Hiromi Tagata; Hisashi Yamada; Hiroshi Komatsu; Shinichiro Ochi; Kiyokazu Atake; Eiichi Katsumoto; Mikio Kido; Taishiro Kishimoto; Taro Suwa; Satoshi Yamamura; Jun-Ichi Iga; Hitoshi Iida; Ken Inada; Koichiro Watanabe; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2022-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.